Keros Therapeutics - KROS Operating Profitability

KROS (Keros Therapeutics, Inc.) - company brandmark

Keros Therapeutics specializes in hematology innovations, utilizing TGF-beta proteins to combat rare blood pathologies. This chart on GURU.Markets shows that the operating margin has reached -179.50. Keros Therapeutics is implementing eco-friendly chemical disposal methods to minimize environmental impact. Meanwhile, business success depends on the pace of clinical trials amid fierce industry competition.

KROS: Keros Therapeutics, Inc. Operating Margin 07/04/2022 - 11/20/2026

Metric breakdowns and analytics for kerostx.com (KROS)

- price and consensus price forecast:
Fundamental company valuation:KROS, kerostx.com
Finished products of Keros Therapeutics

This metric reflects the internal efficiency of the business through the ratio of operating profit to revenue. It measures the company's ability to generate income before accounting for debt load and taxes. For Keros Therapeutics (KROS), this indicator depends critically on the optimization of R&D expenses during the development of the KER-050 modulator. Effective cost control directly impacts the issuer's cash runway. By analyzing operating margin fluctuations, an investor can timely recognize signs of financial stability or hidden decline.